Preora Diagnostics Inc. is dedicated to helping people survive cancer through a proven, two-tiered approach to early detection. We are developing proprietary, low-cost, minimally invasive and highly sensitive cancer screening tests using technology that detects and measures cellular changes at the nanoscale level. This change has been successfully tested as potential new biomarkers in more than 1,500 patients in seven different cancer types.
Our screening tools use proprietary technology – Partial Wave Spectroscopy (PWS) Nanocytology – to detect these cellular changes. PWS-based tests may aid in risk assessment and early detection of cancers in high-risk, asymptomatic patients. Tests results may provide physicians with information that they need to encourage patients to comply with national screening guidelines for lung, colon and other solid-tumor cancers.
We anticipate widespread adoption of our tests by primary care physicians as adjuncts to traditional cancer screening tools, such as Low-Dose Computed Tomography (LDCT) and colonoscopy.